000			01932 a2200553 4500
005			20250514225905.0
264		0	_c20050715
008			200507s 0 0 eng d
022			_a0014-4886
024	7		_a10.1016/j.expneurol.2005.02.002 _2doi
040			_aNLM _beng _cNLM
100	1		_aLundblad, M
245	0	0	_aPharmacological validation of a mouse model of l-DOPA-induced dyskinesia. _h[electronic resource]
260			_bExperimental neurology _cJul 2005
300			_a66-75 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Validation Study
650	0	4	_aAdenosine A2 Receptor Agonists
650	0	4	_aAdrenergic Agents _xadverse effects
650	0	4	_aAmantadine _xpharmacology
650	0	4	_aAnimals
650	0	4	_aAntiparkinson Agents _xpharmacology
650	0	4	_aBasal Ganglia _xdrug effects
650	0	4	_aBuspirone _xpharmacology
650	0	4	_aDisease Models, Animal
650	0	4	_aDisease Progression
650	0	4	_aDopamine Agonists _xpharmacology
650	0	4	_aDrug Administration Schedule
650	0	4	_aDyskinesia, Drug-Induced _xdrug therapy
650	0	4	_aIndoles _xpharmacology
650	0	4	_aLevodopa _xadministration & dosage
650	0	4	_aMale
650	0	4	_aMice
650	0	4	_aMice, Inbred C57BL
650	0	4	_aOxidopamine
650	0	4	_aParkinsonian Disorders _xchemically induced
650	0	4	_aPurines _xpharmacology
650	0	4	_aReceptor, Adenosine A2A _xmetabolism
650	0	4	_aReceptors, Dopamine D2 _xagonists
650	0	4	_aReproducibility of Results
650	0	4	_aRiluzole _xpharmacology
650	0	4	_aTreatment Outcome
700	1		_aUsiello, A
700	1		_aCarta, M
700	1		_aHåkansson, K
700	1		_aFisone, G
700	1		_aCenci, M A
773	0		_tExperimental neurology _gvol. 194 _gno. 1 _gp. 66-75
856	4	0	_uhttps://doi.org/10.1016/j.expneurol.2005.02.002 _zAvailable from publisher's website
999			_c15561526 _d15561526